Blood Tests of Immunological Biomarkers can predict the outcomes of Cytoreductive Surgery (Complete Tumor and Tumor Deposit Removal) and Hyperthermic Intraperitoneal Chemotherapy (Heated Chemotherapy in the abdomen during Surgery), in Ovarian Cancer patients
Not Applicable
- Conditions
- Health Condition 1: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2023/01/049023
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patientâ??s requiring Upfront Cytoreductive Surgery and Interval
Cytoreduction after Chemotherapy
2. Cytology or Biopsy proven Epithelial Ovarian malignancies
3. Localized Metastasis on Imaging (CECT scans will be the most commonly
used investigation, as per institutional protocol)
4. Good Performance status (KPS-100-40 or ECOG -0-2)
5. Age >18 yrs < 70 years (extremes of age is to be avoided due to
anticipation of the morbidity of the surgery)
6. Preexisting co-morbid conditions that DONOT preclude CRS and HIPEC
7. ASA I to III
Exclusion Criteria
1. Patient NOT consenting for Cytoreductive Surgery and HIPEC
2. Co morbidities that are a constant threat to the patientâ??s life
3. Poor performance Status and ASA IV and V
4. Study drop out
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method